Core Viewpoint - The company has submitted an application for the Phase III clinical trial of IMM0306 to the National Medical Products Administration of China, marking a significant step in its development of a dual-targeting bispecific molecule for cancer treatment [1] Group 1: Product Development - IMM0306 is a dual-targeting bispecific molecule that targets CD47 and CD20, making it the first of its kind to enter clinical stages globally [1] - The mechanism of IMM0306 involves inhibiting the CD47-SIRPα interaction to block the "don't eat me" signal, enhancing the interaction between Fc-FcɣRIIa and Fc-FcɣRIIIa to activate macrophages and NK cells [1] - The molecule preferentially binds to CD20 rather than CD47, effectively eliminating malignant B cells while minimizing toxicity, which could improve treatment outcomes [1] Group 2: Intellectual Property and Commercial Rights - The company holds global intellectual property and commercialization rights for IMM0306 as of the date of the announcement [1]

Core Viewpoint - The company has submitted an application for the Phase III clinical trial of IMM0306 to the National Medical Products Administration of the People's Republic of China, marking a significant step in its development of a novel dual-targeting bispecific molecule [1] Group 1: Product Development - IMM0306 is a dual-targeting bispecific molecule that targets CD47 and CD20, making it the first of its kind to enter clinical stages globally [1] - The mechanism of IMM0306 involves inhibiting the CD47-SIRPα interaction to block the "don't eat me" signal, thereby enhancing the activation of macrophages and NK cells [1] - The molecule preferentially binds to CD20 rather than CD47, which allows for effective elimination of malignant B cells while minimizing toxicity, potentially improving treatment outcomes [1] Group 2: Intellectual Property and Commercialization - The company holds global intellectual property and commercialization rights for IMM0306 as of the date of the announcement [1]

Core Viewpoint - The company has submitted an application for the Phase III clinical trial of IMM0306 to the National Medical Products Administration of China, marking a significant step in the development of a novel dual-targeting bispecific molecule for cancer treatment [1] Group 1: Product Development - IMM0306 is a dual-targeting bispecific molecule that targets CD47 and CD20, making it the first of its kind to enter clinical stages globally [1] - The mechanism of IMM0306 involves inhibiting the CD47-SIRPα interaction to block the "don't eat me" signal, enhancing the interaction between Fc-Fc RIIa and Fc-Fc RIIIa to activate macrophages and NK cells [1] - The molecule preferentially binds to CD20 rather than CD47, effectively eliminating malignant B cells while minimizing toxicity, thereby improving therapeutic outcomes [1] Group 2: Intellectual Property and Commercialization - The company holds global intellectual property and commercialization rights for IMM0306 as of the date of the announcement [1]

36氪获悉，长春高新公告，公司已于2025年9月29日向香港联合交易所有限公司（以下简称"香港联交 所"）递交了发行境外上市外资股（H股）股票并在香港联交所主板上市（以下简称"本次发行上市"） 的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。本次发行上市事项的相关申请资 料为公司按照香港证券及期货事务监察委员会及香港联交所的要求编制和刊发，为草拟版本，其所载资 料可能会适时作出更新及修订，投资者不应根据其中的资料作出任何投资决定。 ...

Core Viewpoint - Shanghai Kaisa Biotechnology Co., Ltd. announced the authorization for its non-wholly-owned subsidiaries to provide guarantees for credit applications and daily operations, with a total guarantee limit not exceeding 2 billion yuan [1] Group 1 - The total amount of guarantees provided by non-wholly-owned subsidiaries as of the announcement date is 500 million yuan, all of which are inter-subsidiary guarantees [1] - The main entities being guaranteed include Kaisa (Taiyuan) Biomaterials Co., Ltd. and Kaisa (Taiyuan) Biotechnology Co., Ltd., both of which have a debt-to-asset ratio not exceeding 70% [1] - The authorization has been approved by the board of directors and does not require shareholder meeting approval, indicating that the guarantee risks are controllable and do not harm the interests of the company and its shareholders [1]

Core Viewpoint - Haiwang Bio (000078) announced revisions to its Articles of Association and multiple company systems to enhance corporate governance and operational standards [1][5]. Group 1: Background and Reasons for Revisions - The revisions are based on legal requirements from the Company Law and related regulatory documents, tailored to the company's actual situation [2]. - The supervisory board's powers will be transferred to the board's audit committee, leading to the abolition of the supervisory board's meeting rules [2]. Group 2: Key Points of the Articles of Association Revisions - Legal representative provisions clarify that if a director or president resigns, they are deemed to have also resigned as the legal representative, with a new representative to be appointed within 30 days [3]. - Shareholder rights and obligations have been detailed, including the right to request the company to buy back shares in case of dissent regarding merger or division resolutions [3]. - Directors' duties have been reinforced, emphasizing loyalty and diligence, with provisions for income from violations to be returned to the company and liability for losses incurred [3]. - The governance structure will see the audit committee assume the supervisory board's functions, with defined roles and procedures for the nomination and remuneration committees [3]. Group 3: Revisions to Meeting Rules - The "Shareholders' Meeting Rules" have been updated to replace "Shareholders' General Meeting" with "Shareholders' Meeting" and adjust procedures for convening temporary meetings and voting rules [4]. - The "Board Meeting Rules" have been refined to enhance the election, replacement, and resignation processes of directors, emphasizing the independence and responsibilities of independent directors [4]. Group 4: Implementation of Revised Systems - A total of 26 company systems have been established or revised, covering areas such as shareholder meetings, board meetings, auditing, and fundraising management [5]. - Six of these systems, including the "Shareholders' Meeting Rules" and "Board Meeting Rules," require approval from the shareholders' meeting to take effect, while others will be effective upon board approval [5]. - The merger of the "Independent Director Special Meeting System" into the "Independent Director Work System" has been executed, with the former being abolished [5].

Core Viewpoint - Shenzhen Haiwang Bioengineering Co., Ltd. has released a draft of its revised company articles aimed at improving corporate governance, operational efficiency, and protecting the rights of shareholders and the company [1][2]. Group 1: Company Structure and Governance - The company was established in 1998 with a registered capital of RMB 2,631,123,257.00, and it operates in various fields including biochemical raw materials, pharmaceuticals, and investment [1][2]. - The total number of shares is 2,631,123,257, all of which are ordinary shares, with initial issuance of 57,300,000 shares by five founding shareholders [2]. - The governance structure includes a board of directors consisting of 7 to 9 members, with independent directors making up at least one-third of the board [2]. Group 2: Shareholder Rights and Responsibilities - Shareholders have rights to dividends and participation in shareholder meetings, while also being required to comply with legal obligations and company regulations [2]. - The shareholder meeting is responsible for major decisions such as director elections and profit distribution, with specific procedures for convening and voting [2]. Group 3: Financial and Audit Regulations - The company is required to establish financial accounting systems and disclose annual and interim reports in a timely manner [2]. - Profit distribution policies will focus on investor returns and may include cash or stock options, depending on the company's development stage [2]. - An internal audit system is in place to oversee financial practices and the appointment of external auditors [2].

公告称，考虑到具有浮动回报的保本理财产品的性质，预期回报率，及理财产品的中短期性质，使用集 团闲置自有资金认购中国银行结构性存款将获得高于一般商业银行存款的回报，并且有利于提高集团闲 置资金的使用效率。董事认为中国银行结构性存款的条款属公平合理，并符合公司股东的整体利益。 智通财经APP讯，科伦博泰生物-B(06990)发布公告，2025年9月29日，公司订立中国银行结构性存款协 议，据此，公司同意认购本金额为人民币4.4亿元的中国银行结构性存款。 ...

格隆汇9月29日丨科伦博泰生物-B(06990.HK)公告，2025年9月29日，公司订立中国银行结构性存款协 议，据此，公司同意认购本金额为人民币4.4亿元的中国银行结构性存款。 ...

公告称，考虑到具有浮动回报的保本理财产品的性质，预期回报率，及理财产品的中短期性质，使用集 团闲置自有资金认购中国银行结构性存款将获得高于一般商业银行存款的回报，并且有利于提高集团闲 置资金的使用效率。董事认为中国银行结构性存款的条款属公平合理，并符合公司股东的整体利益。 科伦博泰生物-B(06990)发布公告，2025年9月29日，公司订立中国银行结构性存款协议，据此，公司同 意认购本金额为人民币4.4亿元的中国银行结构性存款。 ...